Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy



Page Path
HOME > Clin Endosc > Volume 35(1); 2007 > Article
Comparison of the Eradication Rates of One-week Low-dose Triple Therapy with Standard-dose Triple Therapy for Helicobacter pylori Infection
[Epub ahead of print]
Published online: July 30, 2007
Department of Internal Medicine and the Liver Research Institute, Seoul National University Hospital, Seoul, *Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
  • 15 Download
  • 0 Crossref
  • 0 Scopus

/Aims: We can expect to reduce costs and decrease adverse events by using low-dose triple therapy for H. pylori eradication. However, the efficacy of low-dose triple therapy for Koreans is questionable. In this study, we compared the efficacy of low-dose triple therapy with standard-dose triple therapy. Methods: We enrolled 480 patients who were diagnosed as suffering with H. pylori infection via endoscopy with biopsy or CLO testing. Thirty patients were excluded due to malignancy or having undergone previous antibiotics medication. Two hundred and eighty patients received standard-dose triple therapy (pantoprazole 40 mg b.d, amoxicillin 1,000 mg b.d., and clarithromycin 500 mg b.d.), and 170 patients received low-dose triple therapy (pantoprazole 40 mg b.d., amoxicillin 750 mg b.d., and clarithromycin 250 mg b.d.). Eradication was evaluated 4∼6 weeks after administering the medication. Results: The H. pylori eradication rate was 77.9% in the standard-dose group, and 74.7% in the low-dose group. There was no significant difference in the H. pylori eradication rate between the two groups (p=0.444). The adverse events were significantly more frequent in the standard-dose group. One patient each in both groups discontinued medication because of an adverse event. Conclusions: The efficacy of low-dose therapy is similar to standard-dose therapy, and the adverse events are less frequent with low-dose therapy. This suggests that low-dose therapy would be preferred when considering the cost- benefit and low rate of adverse drug events.

Clin Endosc : Clinical Endoscopy Twitter Facebook
Close layer